Oramed Pharmaceuticals Inc. (ORMP) · Nov 19, 2026 · Other events

Oramed settles bylaw lawsuit with $125,000 fee

$125,000 legal settlement — $125,000 attorneys’ fees and expenses

Oramed’s legal filing closes a mooted bylaw challenge with a $125,000 fee payment, adding little to its already reshaped business story.

Oramed is now a strategic holding and development vehicle rather than a conventional operating biotech: after transferring its oral-insulin platform to OraTech and closing the Lifeward transaction, it no longer conducts clinical development directly or has revenue-generating operations, and is evaluating new strategic alternatives.

This filing closes a stale corporate-governance dispute, not a business issue. The bylaw amendment mooted the case on June 28, 2026, and the court dismissed it on July 2 while retaining jurisdiction only over legal fees. 〔0〕

The only new economic item is a modest $125,000 payment. Oramed agreed to pay plaintiff’s counsel’s fees and expenses without admitting fault or wrongdoing. Relative to Oramed’s broader strategic transition, this is immaterial and does not alter its assets, pipeline ownership, operating model, or strategic options.

Bottom line: This is legal housekeeping that formally resolves an already-mooted bylaw challenge. It does not change Oramed’s underlying business story or strategic transition.

Original filing on SEC EDGAR

Oramed settles bylaw lawsuit with $125,000 fee | ORMP Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.